This is why Intra-Cellular Therapies Inc. (ITCI) Stock is one of the options for the Longer run

Currently, Intra-Cellular Therapies Inc. [ITCI] is trading at $45.71, up 3.30%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ITCI shares have lost -9.54% over the last week, with a monthly amount drifted -8.29%, and not seem to be holding up well over a long-time horizon.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


On 9, August 2022, Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase.

From an analyst’s perspective:

Intra-Cellular Therapies Inc. [NASDAQ: ITCI] stock has seen the most recent analyst activity on August 22, 2022, when Goldman downgraded its rating to a Neutral and also revised its price target to $49 from $64. Previously, Mizuho started tracking the stock with Buy rating on July 07, 2022, and set its price target to $74. On June 14, 2022, UBS initiated with a Buy rating and assigned a price target of $75 on the stock. Piper Sandler started tracking the stock assigning a Neutral rating and suggested a price target of $59 on April 22, 2022. Goldman initiated its recommendation with a Buy and recommended $64 as its price target on February 16, 2022. Needham started tracking with a Buy rating for this stock on September 23, 2021, and assigned it a price target of $55. In a note dated December 15, 2020, BofA Securities initiated an Buy rating and iterated a target price of $40 on this stock.

This stock has fluctuated between a low of $34.43 and a high of $66.00 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $69.15 within the next 12 months. Intra-Cellular Therapies Inc. [NASDAQ: ITCI] shares were valued at $45.71 at the most recent close of the market. An investor can expect a potential return of 51.28% based on the average price forecast.

Analyzing the ITCI fundamentals

Recent quarter sales for Intra-Cellular Therapies Inc. [NASDAQ:ITCI] were 55.58 billion which represents 178.00% growth. Gross Margin for this corporation currently stands at +90.41% with Operating Margin at -340.90%, Pretax Margin comes in at -339.03%, and Net Margin reading is -339.04%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 43.65 points at the first support level, and at 41.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 47.06, and for the 2nd resistance point, it is at 48.40.

Intra-Cellular Therapies Inc. [ITCI] reported earnings per share of -$0.78 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.92/share, meaning a difference of $0.14 and a surprise factor of 15.20%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$1.05 per share as compared to estimates of -$0.99 per share, a difference of $-0.06 representing a surprise of -6.10%.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Intra-Cellular Therapies Inc. [NASDAQ:ITCI] is 11.20. As well, the Quick Ratio is 8.61, while the Cash Ratio is 7.75. Considering the valuation of this stock, the price to sales ratio is 50.75, the price to book ratio is 10.26.

Transactions by insiders

Insider trading has also been a hot topic recently, with 4 insiders purchasing 30,397 shares and 3 selling 40,000 shares in the past 3 months. Recent insider trading involved MARCUS JOEL S, Director, that happened on Aug 11 when 10000.0 shares were sold. Director, VAN NOSTRAND ROBERT L completed a deal on Aug 11 to sell 30000.0 shares. Meanwhile, Director MARCUS JOEL S sold 10000.0 shares on May 12.